Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus

Abstract

Key Points Question What is the efficacy and safety of ruxolitinib cream in patients with cutaneous lichen planus? Findings In this randomized clinical trial of 64 adults with predominantly cutaneous lichen planus, significantly more patients who applied ruxolitinib, 1.5%, cream vs vehicle experienced Investigator’s Global Assessment (IGA) treatment success (IGA 0/1 [clear/almost clear skin] with a ≥2-grade improvement from baseline; 50.0% vs 21.9%) at week 16 (continuous twice daily treatment), with further improvement to week 32 (as needed twice daily treatment). No serious treatment-emergent adverse events were observed with ruxolitinib cream. Meaning The trial results suggest that ruxolitinib cream may be an effective nonsteroidal treatment for cutaneous lichen planus.